Supply Chain news and information

A senior Senate Democrat aims to expedite legislation that would establish both a track-and-trace system for drugs and a new regulatory framework for compounding pharmacies.
FULL STORY »

The first Missouri doctor to receive an emergency suspension in at least 25 years can practice medicine again, with some restrictions. The license of the Jefferson City cardiologist had been suspended in November when he was accused of unnecessarily placing stents in patients' coronary arteries.
FULL STORY »

The average cost for anesthesia units is 14% higher than it was a year ago, according to the Modern Healthcare/ECRI Institute Technology Price Index.
FULL STORY »

Actavis is buying Warner Chilcott in an all-stock transaction valued at about $8.5 billion which would create the third-biggest specialty pharmaceutical company in the U.S.
FULL STORY »

In the old days, sales representatives from drug companies would chat up local pharmacists to learn what drugs doctors were prescribing. Now such shoulder-rubbing is becoming a quaint memory—thanks to vast databases of patient and doctor information being used by pharmaceutical companies to...
FULL STORY »

A heated takeover battle has erupted around generic-drug company Actavis as industry players seek to shore themselves up amid increasing competition and fewer new knock-off-drug opportunities.
FULL STORY »

Cancer researchers are growing increasingly enthusiastic about harnessing the body's own immune system to fight tumors.
FULL STORY »

The Food and Drug Administration has approved a new injectable drug that uses radiation to treat advanced prostate cancer that has spread to the bones.
FULL STORY »

A new study is questioning the benefits of dual-chamber implantable cardioverter-defibrillators.
FULL STORY »

The Indian generic drugmaker Ranbaxy, which already operates under an unprecedented consent decree banning sales of many of its products in the U.S., agreed to plead guilty in federal court and pay $500 million to resolve allegations of shoddy factory inspections and poor quality control.
FULL STORY »